Rifampicin

Last updated
Rifampicin
Rifampicin structure.svg
Rifampicin 3D 1i6v.png
Clinical data
Pronunciation /rɪˈfæmpəsɪn/
Trade names Rifadin, others
Other namesRifampin (USAN US)
AHFS/Drugs.com Monograph
MedlinePlus a682403
License data
Pregnancy
category
  • AU:C
Routes of
administration 		By mouth, Intravenous therapy
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 90 to 95% (by mouth)
Protein binding 80%
Metabolism Liver and intestinal wall
Elimination half-life 3–4 hours
Excretion Urine (~30%), faeces (60–65%)
Identifiers
  • (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.032.997 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C43H58N4O12
Molar mass 822.953 g·mol−1
3D model (JSmol)
Melting point 183 to 188 °C (361 to 370 °F)
Boiling point 937 °C (1,719 °F) [2]
  • CN1CCN(CC1)/N=C/c2c(O)c3c5C(=O)[C@@]4(C)O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(\C)C(=O)Nc2c(O)c3c(O)c(C)c5O4
  • InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1 Yes check.svgY
  • Key:JQXXHWHPUNPDRT-WLSIYKJHSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires' disease. [3] It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" [4] for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. [3] Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. [3] Rifampicin may be given either by mouth or intravenously. [3]

Contents

Common side effects include nausea, vomiting, diarrhea, and loss of appetite. [3] It often turns urine, sweat, and tears a red or orange color. [3] Liver problems or allergic reactions may occur. [3] It is part of the recommended treatment of active tuberculosis during pregnancy, though its safety in pregnancy is not known. [3] Rifampicin is of the rifamycin group of antibiotics. [3] It works by decreasing the production of RNA by bacteria. [3]

Rifampicin was discovered in 1965, marketed in Italy in 1968, and approved in the United States in 1971. [5] [6] [7] It is on the World Health Organization's List of Essential Medicines. [8] The World Health Organization classifies rifampicin as critically important for human medicine. [9] It is available as a generic medication. [3] Rifampicin is made by the soil bacterium Amycolatopsis rifamycinica . [7]

Medical uses

Rifampicin powder Rifampicin powder.JPG
Rifampicin powder

Mycobacteria

Rifampicin is used for the treatment of tuberculosis in combination with other antibiotics, such as pyrazinamide, isoniazid, and ethambutol. [10] For the treatment of tuberculosis, it is administered daily for at least six months. [11] Combination therapy is used to prevent the development of resistance and to shorten the length of treatment. [12] Resistance of Mycobacterium tuberculosis to rifampicin develops quickly when it is used without another antibiotic, with laboratory estimates of resistance rates from 10−7 to 10−10 per tuberculosis bacterium per generation. [13] [14]

Rifampicin can be used alone in patients with latent tuberculosis infections to prevent or delay the development of active disease because only small numbers of bacteria are present. A Cochrane review found no difference in efficacy between a 3- to 4-month regimen of rifampicin and a 6-month regimen of isoniazid for preventing active tuberculosis in patients not infected with HIV, and patients who received rifampicin had a lower rate of hepatotoxicity. [15] However, the quality of the evidence was judged to be low. [15] A shorter 2-month course of rifampicin and pyrazinamide had previously been recommended but is no longer recommended due to high rates of hepatotoxicity. [16]

Rifampicin should be taken on an empty stomach with a glass of water. It is generally taken either at least one hour before meals or two hours after meals. [17]

Rifampicin is also used to treat nontuberculous mycobacterial infections including leprosy (Hansen's disease) and Mycobacterium kansasii . [18]

With multidrug therapy used as the standard treatment of Hansen's disease, rifampicin is always used in combination with dapsone and clofazimine to avoid causing drug resistance.[ citation needed ]

It is also used in the treatment of Mycobacterium ulcerans infections as associated with Buruli ulcer, usually in combination with clarithromycin or other antibiotics. [19]

Other bacteria and protozoans

In 2008, tentative evidence showed rifampicin may be useful in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in combination with other antibiotics, including in difficult-to-treat infections such as osteomyelitis and prosthetic joint infections. [20] As of 2012, if rifampicin combination therapy was useful for pyogenic vertebral osteomyelitis was unclear. [21] A meta-analysis concluded that adding adjunctive rifampicin to a β-lactam or vancomycin may improve outcomes in staphylococcus aureus bacteremia. [22] However, a more recent trial found no benefit from adjunctive rifampicin. [23]

It is also used as preventive treatment against Neisseria meningitidis (meningococcal) infections. Rifampicin is also recommended as an alternative treatment for infections by the tick-borne pathogens Borrelia burgdorferi and Anaplasma phagocytophilum when treatment with doxycycline is contraindicated, such as in pregnant women or in patients with a history of allergy to tetracycline antibiotics. [24] [25]

It is also sometimes used to treat infections by Listeria species, Neisseria gonorrhoeae , Haemophilus influenzae , and Legionella pneumophila . For these nonstandard indications, antimicrobial susceptibility testing should be done (if possible) before starting rifampicin therapy.[ citation needed ]

The Enterobacteriaceae, Acinetobacter species, and Pseudomonas species are intrinsically resistant to rifampicin.[ citation needed ]

It has been used with amphotericin B in largely unsuccessful attempts to treat primary amoebic meningoencephalitis caused by Naegleria fowleri .[ citation needed ]

Rifampicin can be used as monotherapy for a few days as prophylaxis against meningitis, but resistance develops quickly during long-term treatment of active infections, so the drug is always used against active infections in combination with other antibiotics. [26]

Rifampicin is relatively ineffective against spirochetes, which has led to its use as a selective agent capable of isolating them in materials being cultured in laboratories. [27]

Viruses

Rifampicin has some effectiveness against vaccinia virus. [28] [29]

Pathogen susceptibility

The minimum inhibitory concentrations of rifampicin for several medically significant pathogens are:

Primary biliary cholangitis

Rifampicin is used to treat itchiness caused by primary biliary cholangitis. The treatment-related adverse effects include hepatotoxicity, nephrotoxicity, hemolysis, and interactions with other drugs. [32] For those reasons as well as some ethical concerns regarding off-label use of antibiotics, rifampin as a very effective preventive antibiotic for meningitis, is not considered appropriate for itchiness. [33] [34] [35]

Hidradenitis suppurativa

Rifampicin with clindamycin has been used to treat the skin disease hidradenitis suppurativa. [36]

Adverse effects

The most serious adverse effect is hepatotoxicity, and people receiving it often undergo baseline and frequent liver function tests to detect early liver damage. [37]

The more common side effects include fever, gastrointestinal disturbances, rashes, and immunological reactions. Taking rifampicin usually causes certain bodily fluids, such as urine, sweat, and tears, to become orange-red in color, a benign side effect that nonetheless can be frightening if it is not expected. This may also be used to monitor effective absorption of the drug (if drug color is not seen in the urine, the patient may wish to move the drug dose farther in time from food or milk intake). The discolorization of sweat and tears is not directly noticeable, but sweat may stain light clothing orange, and tears may permanently stain soft contact lenses. Since rifampicin may be excreted in breast milk, breastfeeding should be avoided while it is being taken.[ citation needed ]

Other adverse effects include:

Chemical structure

Rifampicin is a polyketide belonging to the chemical class of compounds termed ansamycins, so named because of their heterocyclic structure containing a naphthoquinone core spanned by an aliphatic ansa chain. The naphthoquinonic chromophore gives rifampicin its characteristic red-orange crystalline color.[ citation needed ]

The critical functional groups of rifampicin in its inhibitory binding of bacterial RNA polymerase are the four critical hydroxyl groups of the ansa bridge and the naphthol ring, which form hydrogen bonds with amino acid residues on the protein. [40]

Rifampicin is the 3-(4-methyl-1-piperazinyl)-iminomethyl derivative of rifamycin SV. [41]

Interactions

Rifampicin is the most powerful known inducer of the hepatic cytochrome P450 enzyme system, including isoenzymes CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP3A5, and CYP3A7. [42] It increases metabolism of many drugs [43] and as a consequence, can make them less effective, or even ineffective, by decreasing their levels. [44] For instance, patients undergoing long-term anticoagulation therapy with warfarin have to increase their dosage of warfarin and have their clotting time checked frequently because failure to do so could lead to inadequate anticoagulation, resulting in serious consequences of thromboembolism. [45]

Rifampicin can reduce the efficacy of birth control pills or other hormonal contraception by its induction of the cytochrome P450 system, to the extent that unintended pregnancies have occurred in women who use oral contraceptives and took rifampicin even for very short courses (for example, as prophylaxis against exposure to bacterial meningitis).[ citation needed ]

Other interactions include decreased levels and less effectiveness of antiretroviral agents, everolimus, atorvastatin, rosiglitazone, pioglitazone, celecoxib, clarithromycin, caspofungin, voriconazole, and lorazepam. [46]

Rifampicin is antagonistic to the microbiologic effects of the antibiotics gentamicin and amikacin. The activity of rifampicin against some species of mycobacteria can be potentiated by isoniazid (through inhibiting mycolate synthesis) [47] and ambroxol (through host directed effects in autophagy and pharmacokinetics). [48]

Pharmacology

Mechanism of action

Binding of rifampicin in the active site of RNA polymerase. Mutation of amino acids shown in red are involved in resistance to the antibiotic. Rifampicin RNApol.png
Binding of rifampicin in the active site of RNA polymerase. Mutation of amino acids shown in red are involved in resistance to the antibiotic.

Rifampicin inhibits bacterial DNA-dependent RNA synthesis by inhibiting bacterial DNA-dependent RNA polymerase. [49]

Crystal structure data and biochemical data suggest that rifampicin binds to the pocket of the RNA polymerase β subunit within the DNA/RNA channel, but away from the active site. [40] The inhibitor prevents RNA synthesis by physically blocking elongation, and thus preventing synthesis of host bacterial proteins. By this "steric-occlusion" mechanism, rifampicin blocks synthesis of the second or third phosphodiester bond between the nucleotides in the RNA backbone, preventing elongation of the 5' end of the RNA transcript past more than 2 or 3 nucleotides. [40] [50]

In a recent study Rifampicin was shown to bind to cytochrome P450 reductase and alter its conformation as well as activity towards supporting metabolism of progesterone via CYP21A2. [51]

Mechanism of resistance

Resistance to rifampicin arises from mutations that alter residues of the rifampicin binding site on RNA polymerase, resulting in decreased affinity for rifampicin. [50] Resistance mutations map to the rpoB gene, encoding the beta subunit of RNA polymerase. The majority of resistance mutations in E. coli are in 3 clusters on rpoB. [13] Cluster I is amino acids 509 to 533, cluster II is amino acids 563 to 572, and cluster III is amino acid 687.[ citation needed ]

When describing mutations in rpoB in other species, the corresponding amino acid number in E. coli is usually used. In Mycobacterium tuberculosis, the majority of mutations leading to rifampicin resistance are in cluster I, in a 81bp hotspot core region called RRDR for "rifampcin resistance determining region". [52] A change in amino acid 531 from serine to leucine arising from a change in the DNA sequence of TCG to TTG is the most common mutation. [13] Tuberculosis resistance has also occurred due to mutations in the N-terminal region of rpoB and cluster III. [13]

An alternative mechanism of resistance is through Arr-catalyzed ADP-ribosylation of rifampicin. With the assistance of the enzyme Arr produced by the pathogen  Mycobacterium smegmatis, ADP-ribose is added to rifampicin at one of its ansa chain hydroxy groups, thereby inactivating the drug. [53]

Resistance in tuberculosis

Mycobacterial resistance to rifampicin may occur alone or along with resistance to other first-line antitubercular drugs. Early detection of such multidrug or extensively drug-resistant tuberculosis is critical in improving patient outcomes by instituting appropriate second-line treatments, and in decreasing transmission of drug-resistant TB. [54] Traditional methods of detecting resistance involve mycobacterial culture and drug susceptibility testing, results of which could take up to 6 weeks. Xpert MTB/RIF assay is an automated test that can detect rifampicin resistance, and also diagnose tuberculosis. A Cochrane review updated in 2014 and 2021 concluded that for rifampicin resistance detection, Xpert MTB/RIF was accurate, that is (95%) sensitive and (98%) specific. [55]

Pharmacokinetics

Orally administered rifampicin results in peak plasma concentrations in about 2–4 hours. 4-Aminosalicylic acid (another antituberculosis drug) significantly reduces absorption of rifampicin, [56] and peak concentrations may be lower. If these two drugs must be used concurrently, they must be given separately, with an interval of 8 to 12 hours between administrations.[ citation needed ]

Rifampicin is easily absorbed from the gastrointestinal (GI) tract; its ester functional group is quickly hydrolyzed in bile, and it is catalyzed by a high pH and substrate-specific esterases. After about 6 hours, almost all of the drug is deacetylated. Even in this deacetylated form, rifampicin is still a potent antibiotic; however, it can no longer be reabsorbed by the intestines and is eliminated from the body. Only about 7% of the administered drug is excreted unchanged in urine, though urinary elimination accounts for only about 30% of the drug excretion. About 60% to 65% is excreted through feces.[ citation needed ]

The half-life of rifampicin ranges from 1.5 to 5.0 hours, though hepatic impairment significantly increases it. Food consumption inhibits its absorption from the GI tract, and the drug is more quickly eliminated. When rifampicin is taken with a meal, its peak blood concentration falls by 36%. Antacids do not affect its absorption. [57] The decrease in rifampicin absorption with food is sometimes enough to noticeably affect urine color, which can be used as a marker for whether or not a dose of the drug has been effectively absorbed.[ citation needed ]

Distribution of the drug is high throughout the body, and reaches effective concentrations in many organs and body fluids, including the cerebrospinal fluid. Since the substance itself is red, this high distribution is the reason for the orange-red color of the saliva, tears, sweat, urine, and feces. About 60% to 90% of the drug is bound to plasma proteins. [58]

Use in biotechnology

Rifampicin inhibits bacterial RNA polymerase, and is commonly used to inhibit the synthesis of host bacterial proteins during recombinant protein expression in bacteria. RNA encoding for the recombinant gene is usually transcribed from DNA by a viral T7 RNA polymerase, which is not affected by rifampicin.[ citation needed ]

History

In 1957, a soil sample from a pine forest on the French Riviera was brought for analysis to the Lepetit Pharmaceuticals research lab in Milan, Italy. There, a research group headed by Piero Sensi [59] and Maria Teresa Timbal discovered a new bacterium. This new species produced a new class of molecules with antibiotic activity. Because Sensi, Timbal and the researchers were particularly fond of the French crime story Rififi (about a jewel heist and rival gangs), [60] they decided to call these compounds rifamycins. After two years of attempts to obtain more stable semisynthetic products, a new molecule with high efficacy and good tolerability was produced in 1965 and was named rifampicin. [5]

Rifampicin was first sold in Italy in 1968 and was approved by the FDA in 1971. [5]

Society and culture

Cancer-causing impurities

In August 2020, the U.S. Food and Drug Administration (FDA) became aware of nitrosamine impurities in certain samples of rifampin. [61] The FDA and manufacturers are investigating the origin of these impurities in rifampin, and the agency is developing testing methods for regulators and industry to detect the 1-methyl-4-nitrosopiperazine (MNP). [61] MNP belongs to the nitrosamine class of compounds, some of which are classified as probable or possible human carcinogens (substances that could cause cancer), based on laboratory tests such as rodent carcinogenicity studies. [61] Although there are no data available to directly evaluate the carcinogenic potential of MNP, information available on closely related nitrosamine compounds was used to calculate lifetime exposure limits for MNP. [61]

As of January 2021, the FDA continues to investigate the presence of 1-methyl-4-nitrosopiperazine (MNP) in rifampin or 1-cyclopentyl-4-nitrosopiperazine (CPNP) in rifapentine approved for sale in the US. [62]

Names

Rifampicin is the INN and BAN, while rifampin is the USAN. Rifampicin may be abbreviated R, RMP, RA, RF, or RIF (US).[ citation needed ]

Rifampicin is also known as rifaldazine, [63] [64] rofact, and rifampin in the United States, also as rifamycin SV. [65]

Its chemical name is 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)-naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate.[ citation needed ]

Rifampicin is available under many brand names worldwide. [66]

Related Research Articles

<span class="mw-page-title-main">Antibiotic</span> Antimicrobial substance active against bacteria

An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria. A limited number of antibiotics also possess antiprotozoal activity. Antibiotics are not effective against viruses such as the ones which cause the common cold or influenza; drugs which inhibit growth of viruses are termed antiviral drugs or antivirals rather than antibiotics. They are also not effective against fungi; drugs which inhibit growth of fungi are called antifungal drugs.

<i>Mycobacterium tuberculosis</i> Species of pathogenic bacteria that causes tuberculosis

Mycobacterium tuberculosis, also known as Koch's bacillus, is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. First discovered in 1882 by Robert Koch, M. tuberculosis has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid. This coating makes the cells impervious to Gram staining, and as a result, M. tuberculosis can appear weakly Gram-positive. Acid-fast stains such as Ziehl–Neelsen, or fluorescent stains such as auramine are used instead to identify M. tuberculosis with a microscope. The physiology of M. tuberculosis is highly aerobic and requires high levels of oxygen. Primarily a pathogen of the mammalian respiratory system, it infects the lungs. The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.

<span class="mw-page-title-main">Linezolid</span> Antibiotic medication

Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug-resistant tuberculosis. It is used either by injection into a vein or by mouth.

<span class="mw-page-title-main">Isoniazid</span> Antibiotic for treatment of tuberculosis

Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.

<span class="mw-page-title-main">Rifamycin</span> Group of antibiotics

The rifamycins are a group of antibiotics that are synthesized either naturally by the bacterium Amycolatopsis rifamycinica or artificially. They are a subclass of the larger family of ansamycins. Rifamycins are particularly effective against mycobacteria, and are therefore used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections.

<span class="mw-page-title-main">Fusidic acid</span> Antibiotic

Fusidic acid, sold under the brand names Fucidin among others, is a steroid antibiotic that is often used topically in creams or ointments and eyedrops but may also be given systemically as tablets or injections.
As of October 2008, the global problem of advancing antimicrobial resistance has led to a renewed interest in its use.

<span class="mw-page-title-main">Trimethoprim/sulfamethoxazole</span> Combination of two antibiotic drugs

Trimethoprim/sulfamethoxazole, sold under the brand name Bactrim among others, is a fixed-dose combination antibiotic medication used to treat a variety of bacterial infections. It consists of one part trimethoprim to five parts sulfamethoxazole. It is used to treat urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, and cholera, among others. It is used both to treat and prevent pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and other causes of immunosuppression. It can be given orally or intravenous infusion.

<span class="mw-page-title-main">Tuberculosis management</span>

Tuberculosis management describes the techniques and procedures utilized for treating tuberculosis (TB) or simply a treatment plan for TB.

<span class="mw-page-title-main">Pyrazinamide</span> Medication

Pyrazinamide is a medication used to treat tuberculosis. For active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. It is taken by mouth.

<span class="mw-page-title-main">4-Aminosalicylic acid</span> Anti-tuberculosis and anti-inflammatory drug

4-Aminosalicylic acid, also known as para-aminosalicylic acid (PAS) and sold under the brand name Paser among others, is an antibiotic primarily used to treat tuberculosis. Specifically it is used to treat active drug resistant tuberculosis together with other antituberculosis medications. It has also been used as a second line agent to sulfasalazine in people with inflammatory bowel disease such as ulcerative colitis and Crohn's disease. It is typically taken by mouth.

<span class="mw-page-title-main">Antibiotic sensitivity testing</span> Microbiology test used in medicine

Antibiotic sensitivity testing or antibiotic susceptibility testing is the measurement of the susceptibility of bacteria to antibiotics. It is used because bacteria may have resistance to some antibiotics. Sensitivity testing results can allow a clinician to change the choice of antibiotics from empiric therapy, which is when an antibiotic is selected based on clinical suspicion about the site of an infection and common causative bacteria, to directed therapy, in which the choice of antibiotic is based on knowledge of the organism and its sensitivities.

<span class="mw-page-title-main">Rifaximin</span> Antibiotic medication

Rifaximin, is a non-absorbable, broad spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in over more than 30 countries for the treatment of a variety of gastrointestinal diseases like irritable bowel syndrome, and hepatic encephalopathy. It acts by inhibiting RNA synthesis in susceptible bacteria by binding to the RNA polymerase enzyme. This binding blocks translocation, which stops transcription. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

<span class="mw-page-title-main">Rifabutin</span> Chemical compound

Rifabutin (Rfb) is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex. It is typically only used in those who cannot tolerate rifampin such as people with HIV/AIDS on antiretrovirals. For active tuberculosis it is used with other antimycobacterial medications. For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB.

<span class="mw-page-title-main">Rifapentine</span> Chemical compound

Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. In active tuberculosis it is used together with other antituberculosis medications. In latent tuberculosis it is typically used with isoniazid. It is taken by mouth.

The rpoB gene encodes the β subunit of bacterial RNA polymerase and the homologous plastid-encoded RNA polymerase (PEP). It codes for 1342 amino acids in E. coli, making it the second-largest polypeptide in the bacterial cell. It is targeted by the rifamycin family of antibacterials, such as rifampin. Mutations in rpoB that confer resistance to rifamycins do so by altering the protein's drug-binding residues, thereby reducing affinity for these antibiotics.

<span class="mw-page-title-main">Ethionamide</span> Chemical compound

Ethionamide is an antibiotic used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis. It is no longer recommended for leprosy. It is taken by mouth.

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

The Xpert MTB/RIF is a cartridge-based nucleic acid amplification test (NAAT) for simultaneous rapid tuberculosis diagnosis and rapid antibiotic sensitivity test. It is an automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) DNA and resistance to rifampicin (RIF). It was co-developed by the laboratory of Professor David Alland at the University of Medicine and Dentistry of New Jersey (UMDNJ), Cepheid Inc. and Foundation for Innovative New Diagnostics, with additional financial support from the US National Institutes of Health (NIH).

Kerry L. LaPlante is an American pharmacist, academic and researcher. She is the Dean at the University of Rhode Island College of Pharmacy. She is a Professor of Pharmacy and former department Chair of the Department of Pharmacy Practice at the University of Rhode Island, an Adjunct Professor of Medicine at Brown University, an Infectious Diseases Pharmacotherapy Specialist, and the Director of the Rhode Island Infectious Diseases Fellowship and Research Programs at the Veterans Affairs Medical Center in Providence, Rhode Island.

References

  1. ↑ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada . 14 October 2020. Retrieved 17 April 2024.
  2. ↑ "Rifampicin (CAS 13292-46-1)". Santa Cruz Biotechnology Product Block. Santa Cruz Biotechnology. Archived from the original on 27 November 2014. Retrieved 14 November 2014.
  3. 1 2 3 4 5 6 7 8 9 10 11 "Rifampin". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-07. Retrieved Aug 1, 2015.
  4. ↑ Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. (February 2020). "Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020". MMWR. Recommendations and Reports. 69 (1). Centers for Disease Control, Atlanta, GA, USA: 1–11. doi:10.15585/mmwr.rr6901a1. PMC   7041302 . PMID   32053584.
  5. 1 2 3 Sensi P (1983). "History of the development of rifampin". Reviews of Infectious Diseases. 5 (Suppl 3): S402–S406. doi:10.1093/clinids/5.supplement_3.s402. JSTOR   4453138. PMID   6635432.
  6. ↑ Oxford Handbook of Infectious Diseases and Microbiology. OUP Oxford. 2009. p. 56. ISBN   978-0-19-103962-1. Archived from the original on 2015-11-24.
  7. 1 2 McHugh TD (2011). Tuberculosis: diagnosis and treatment. Wallingford, Oxfordshire: CAB International. p. 219. ISBN   978-1-84593-807-9.
  8. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. ↑ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl: 10665/312266 . ISBN   9789241515528.
  10. ↑ World Health Organization (2010). Treatment of tuberculosis: guidelines (Fourth ed.). World Health Organization. hdl:10665/44165. ISBN   978-92-4-154783-3.
  11. ↑ Long, James W. (1991). Essential Guide to Prescription Drugs 1992 . New York: HarperCollins Publishers. pp.  925–929. ISBN   978-0-06-273090-9.
  12. ↑ Erlich H, Doolittle WF, Neuhoff V (1973). Molecular Biology of Rifamycin. New York, NY: MSS Information Corporation. pp. 44–45, 66–75, 124–130.
  13. 1 2 3 4 Goldstein BP (September 2014). "Resistance to rifampicin: a review". The Journal of Antibiotics. 67 (9): 625–630. doi: 10.1038/ja.2014.107 . PMID   25118103.
  14. ↑ David HL (November 1970). "Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis". Applied Microbiology. 20 (5): 810–814. doi:10.1128/aem.20.5.810-814.1970. PMC   377053 . PMID   4991927.
  15. 1 2 Sharma SK, Sharma A, Kadhiravan T, Tharyan P (July 2013). "Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB". The Cochrane Database of Systematic Reviews. 2013 (7): CD007545. doi:10.1002/14651858.CD007545.pub2. PMC   6532682 . PMID   23828580.
  16. ↑ Centers for Disease Control Prevention (CDC); American Thoracic Society (August 2003). "Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003". MMWR. Morbidity and Mortality Weekly Report. 52 (31): 735–739. PMID   12904741.
  17. ↑ "Rifampin oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing – WebMD". WebMD. Archived from the original on 22 November 2014. Retrieved 13 November 2014.
  18. ↑ Chambers HF, Gilbert DN, Eliopoulos GM, Saag MS (2015). The Sanford Guide to Antimicrobial Therapy 2015 . Antimicrobial Therapy; 41 edition. ISBN   978-1-930808-84-3.
  19. ↑ Yotsu RR, Murase C, Sugawara M, Suzuki K, Nakanaga K, Ishii N, Asiedu K (November 2015). "Revisiting Buruli ulcer". The Journal of Dermatology. 42 (11): 1033–41. doi: 10.1111/1346-8138.13049 . PMID   26332541. S2CID   39768846.
  20. ↑ Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG (April 2008). "Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature". Archives of Internal Medicine. 168 (8): 805–819. doi: 10.1001/archinte.168.8.805 . PMID   18443255.
  21. ↑ Pola E, Logroscino CA, Gentiempo M, Colangelo D, Mazzotta V, Di Meco E, Fantoni M (April 2012). "Medical and surgical treatment of pyogenic spondylodiscitis". European Review for Medical and Pharmacological Sciences. 16 (Suppl 2): 35–49. PMID   22655482.
  22. ↑ Russell CD, Lawson McLean A, Saunders C, Laurenson IF (June 2014). "Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteraemia: a systematic review". Journal of Medical Microbiology. 63 (Pt 6): 841–848. doi: 10.1099/jmm.0.072280-0 . PMID   24623637.
  23. ↑ Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, et al. (February 2018). "Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial". Lancet. 391 (10121): 668–678. doi:10.1016/S0140-6736(17)32456-X. PMC   5820409 . PMID   29249276.
  24. ↑ Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. (November 2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases. 43 (9): 1089–1134. doi: 10.1086/508667 . PMID   17029130.
  25. ↑ Thomas RJ, Dumler JS, Carlyon JA (August 2009). "Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis". Expert Review of Anti-Infective Therapy. 7 (6): 709–722. doi:10.1586/eri.09.44. PMC   2739015 . PMID   19681699.
  26. ↑ "Rifampicin". Archived from the original on October 2, 2014. Retrieved August 22, 2014.
  27. ↑ Leschine SB, Canale-Parola E (December 1980). "Rifampin as a selective agent for isolation of oral spirochetes". Journal of Clinical Microbiology. 12 (6): 792–795. doi:10.1128/jcm.12.6.792-795.1980. PMC   273700 . PMID   7309842.
  28. ↑ Charity JC, Katz E, Moss B (March 2007). "Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin". Virology. 359 (1): 227–232. doi:10.1016/j.virol.2006.09.031. PMC   1817899 . PMID   17055024.
  29. ↑ Sodeik B, Griffiths G, Ericsson M, Moss B, Doms RW (February 1994). "Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65". Journal of Virology. 68 (2): 1103–1114. doi:10.1128/JVI.68.2.1103-1114.1994. PMC   236549 . PMID   8289340.
  30. ↑ "Rifampicin (Rifampin) - The Antimicrobial Index Knowledgebase—TOKU-E". toku-e.com. Archived from the original on 2014-12-09.
  31. ↑ Gieffers J, Solbach W, Maass M (October 1998). "In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries". Antimicrobial Agents and Chemotherapy. 42 (10): 2762–2764. doi:10.1128/AAC.42.10.2762. PMC   105936 . PMID   9756794.
  32. ↑ Trivedi HD, Lizaola B, Tapper EB, Bonder A (June 2017). "Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review". The American Journal of Medicine. 130 (6): 744.e1–744.e7. doi: 10.1016/j.amjmed.2017.01.037 . PMID   28238692.
  33. ↑ Parsonage B, Hagglund PK, Keogh L, Wheelhouse N, Brown RE, Dancer SJ (2 November 2017). "Control of Antimicrobial Resistance Requires an Ethical Approach". Frontiers in Microbiology. 8: 2124. doi: 10.3389/fmicb.2017.02124 . PMC   5673829 . PMID   29163414.
  34. ↑ "AboutKidsHealth".
  35. ↑ Littmann J, Viens AM (November 2015). "The Ethical Significance of Antimicrobial Resistance". Public Health Ethics. 8 (3): 209–224. doi:10.1093/phe/phv025. PMC   4638062 . PMID   26566395.
  36. ↑ Saunte DM, Jemec GB (November 2017). "Hidradenitis Suppurativa: Advances in Diagnosis and Treatment". JAMA. 318 (20): 2019–2032. doi:10.1001/jama.2017.16691. PMID   29183082. S2CID   5017318.
  37. ↑ Lewis SM, Dirksen SR, Heitkemper MM, Bucher L, Harding M (5 December 2013). Medical-surgical nursing : assessment and management of clinical problems (9th ed.). St. Louis, Missouri: Elsevier/Mosby. ISBN   978-0-323-10089-2. OCLC   228373703.
  38. ↑ Thangaraju P, Singh H, Punitha M, Giri VC, Ali MS (2015). "Hyperpigmentation, a marker of rifampicin overuse in leprosy patient: An incidental finding". Sudan Medical Monitor. 10 (1): 25–26. doi: 10.4103/1858-5000.157506 . S2CID   74136252.
  39. ↑ "Rifampin oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing—WebMD". WebMD. Archived from the original on 22 November 2014. Retrieved 13 November 2014.
  40. 1 2 3 Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA (March 2001). "Structural mechanism for rifampicin inhibition of bacterial rna polymerase". Cell. 104 (6): 901–912. doi: 10.1016/s0092-8674(01)00286-0 . PMID   11290327. S2CID   8229399.
  41. ↑ Bennett J (2015). Principles and Practice of Infectious Diseases. Elsevier Health Sciences. p. 339.
  42. ↑ "Division of Clinical Pharmacology | Indiana University Department of Medicine". Medicine.iupui.edu. 2011-09-27. Archived from the original on 2011-11-05. Retrieved 2011-11-07.
  43. ↑ "Division of Clinical Pharmacology | Indiana University Department of Medicine". 2012-12-26. Archived from the original on 2012-12-26. Retrieved 2021-07-22.
  44. ↑ Collins RD (1985). Atlas of Drug Reactions. New York, NY: Churchill Livingstone. p. 123.
  45. ↑ Stockley IH (1994). "Anticoagulant Drug Interactions.". Drug Interactions (3rd ed.). Boston: Blackwell Scientific Publications. pp. 274–275.
  46. ↑ Riss J, Cloyd J, Gates J, Collins S (August 2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics". Acta Neurologica Scandinavica. 118 (2): 69–86. doi: 10.1111/j.1600-0404.2008.01004.x . PMID   18384456. S2CID   24453988.
  47. ↑ Mdluli K, Swanson J, Fischer E, Lee RE, Barry CE (March 1998). "Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium". Molecular Microbiology. 27 (6): 1223–1233. doi: 10.1046/j.1365-2958.1998.00774.x . PMID   9570407. S2CID   13764717.
  48. ↑ Choi SW, Gu Y, Peters RS, Salgame P, Ellner JJ, Timmins GS, Deretic V (September 2018). "Ambroxol Induces Autophagy and Potentiates Rifampin Antimycobacterial Activity". Antimicrobial Agents and Chemotherapy. 62 (9): AAC.01019–18. doi:10.1128/AAC.01019-18. PMC   6125555 . PMID   30012752.
  49. ↑ Calvori C, Frontali L, Leoni L, Tecce G (July 1965). "Effect of rifamycin on protein synthesis". Nature. 207 (995): 417–418. Bibcode:1965Natur.207..417C. doi:10.1038/207417a0. PMID   4957347. S2CID   4144738.
  50. 1 2 Feklistov A, Mekler V, Jiang Q, Westblade LF, Irschik H, Jansen R, et al. (September 2008). "Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center". Proceedings of the National Academy of Sciences of the United States of America. 105 (39): 14820–14825. Bibcode:2008PNAS..10514820F. doi: 10.1073/pnas.0802822105 . PMC   2567451 . PMID   18787125.
  51. ↑ Jensen SB, Thodberg S, Parween S, Moses ME, Hansen CC, Thomsen J, et al. (April 2021). "Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase". Nature Communications. 12 (1): 2260. Bibcode:2021NatCo..12.2260J. doi: 10.1038/s41467-021-22562-w . PMC   8050233 . PMID   33859207.
  52. ↑ Pierre-Audiger C, Gicquel B. "The Contribution of Molecular Biology in Diagnosing Tuberculosis and Detecting Antibiotic Resistance" (PDF). Molecular TB. Archived (PDF) from the original on 2017-01-16.
  53. ↑ Baysarowich J, Koteva K, Hughes DW, Ejim L, Griffiths E, Zhang K, et al. (March 2008). "Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr". Proceedings of the National Academy of Sciences of the United States of America. 105 (12): 4886–4891. Bibcode:2008PNAS..105.4886B. doi: 10.1073/pnas.0711939105 . PMC   2290778 . PMID   18349144.
  54. ↑ Policy Framework for Implementing New Tuberculosis Diagnostics (PDF). Geneva: World Health Organization. 2011. Archived (PDF) from the original on 9 October 2016. Retrieved 21 March 2016.
  55. ↑ Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. (February 2021). "Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis". The Cochrane Database of Systematic Reviews. 2 (5): CD009593. doi:10.1002/14651858.CD009593.pub5. PMID   33616229. S2CID   231987831.
  56. ↑ G Curci, A Ninni, A.D'Aleccio (1969) Atti Tavola Rotonda Rifampicina, Taormina, page 19. Edizioni Rassegna Medica, Lepetit, Milano
  57. ↑ Peloquin CA, Namdar R, Singleton MD, Nix DE (January 1999). "Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids". Chest. 115 (1): 12–18. doi:10.1378/chest.115.1.12. PMID   9925057.
  58. ↑ Hardman JG, Limbrid LE, Gilman AG (2001). "Rifampin". The Pharmacological Basis of Therapeutics (10th ed.). United States of America: The McGraw-Hill Companies. pp. 1277–1279.
  59. ↑ "Il chimico che salvò molte vite". corriere.it. Archived from the original on 2014-01-09.
  60. ↑ Aronson J (October 1999). "That's show business". BMJ. 319 (7215): 972. doi:10.1136/bmj.319.7215.972. PMC   1116803 . PMID   10514162.
  61. 1 2 3 4 "FDA works to mitigate shortages of rifampin and rifapentine". U.S. Food and Drug Administration (FDA). 26 August 2020. Retrieved 28 August 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  62. ↑ "Laboratory analysis of rifampin/rifapentine products". U.S. Food and Drug Administration (FDA). 28 January 2021. Retrieved 28 January 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  63. ↑ Moncalvo F, Moreo G (1966). "[Preliminary clinical studies on the use of a new oral rifamycin (Rifaldazine) in the therapy of pulmonary tuberculosis. (Preliminary note)]". Giornale Italiano delle Malattie del Torace. 20 (3): 120–131. PMID   5974175.
  64. ↑ "Rifampicin". Chemical Safety Information from Intergovernmental Organizations. International Programme on Chemical Safety. Archived from the original on 31 October 2017. Retrieved 14 November 2014.
  65. ↑ USgranted 3963705,Bruzzese T,"Process for the preparation of rifampicin",issued 13 November 1979, assigned to Holco Investment Inc.
  66. ↑ "Rifampicin". Drugs.com International.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.